Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Section 4 of 6

Clinical evidence

271 evidence topics · 53 sources

Study summaries

BOND-003 cohort C

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Treatment courses
CourseSchedule
Induction“Weekly x 6”
Maintenance, year 1“Weekly x 3 Q3M for Year 1”
Maintenance, years 2 to 3“Weekly x 3 Q6M for Year 2-3”
Second induction“Weekly x 6 for non-responders”
Study outcomes
Rationale for using complete response at any time as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and disease characteristics, safety population
Characteristicn or value%
Male“83”“74.1”
Female“29”“25.9”
Age, mean (SD), years“72.9 (9.19)”
Age, median (range), years“74.0 (43-90)”
Age under 65 years“19”“17.0”
Age 65 to under 75 years“43”“38.4”
Age 75 years or older“50”“44.6”
Prior BCG instillations, median (range)“12 (7 – 66)”
CIS with high-grade Ta/T1“22”“19.6”
CIS alone“90”“80.4”
At least 1 prior therapy other than BCG“53”“47.3”
Serial adjuvant chemotherapy“34”“30.4”
Systemic immunotherapy“7”“6.3”
ECOG performance status, January 2025 data cutoff
Efficacy results
Complete response at 12 and 24 months, June 23, 2025 cutoff
LandmarkCR rate (95% CI)Participants in CRCR by Kaplan-Meier estimate (95% CI)
12 months“46.4% (36.9, 56.1)”“51 out of 110 patients”“50.7% (40.9, 59.8)”
24 months“41.8% (32.5, 51.6)”“46 out of 110”“42.4% (32.7, 51.7)”
Radical cystectomy: timing and pathologic stage
MeasureValue
Cystectomy any time after first recurrence, n (%)“18 (16.4%)”
Cystectomy within the first year of recurrence, n (%)“17 (15.5%)”
Weeks from recurrence or progression to cystectomy, median (Q1, Q3)“20.0 (14.4, 26.7)”
Stage T0, n (%)“1 (0.9)”
Stage CIS, n (%)“9 (8.2)”
Stage HG Ta, n (%)“1 (0.9)”
Stage T1, n (%)“4 (3.6)”
Stage T2A, n (%)“1 (0.9)”
Stage T2B, n (%)“1 (0.9)”
Stage N2, n (%)“1 (0.9)”
Participants with T0 or NMIBC at cystectomy“15/18 (83.3%) were T0 or NMIBC”
Cystectomy-free and progression-free rates at 24 months in a 2026 translational presentation
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse events in more than 10% of participants, June 23, 2025 cutoff
Preferred term (MedDRA v.26.1)Any grade, n (%)Grade 3 or higher, n (%)
At least 1 treatment-related adverse event“71 (63.4%)”“0 (0)”
Bladder spasm“28 (25.0%)”“0 (0)”
Pollakiuria“25 (22.3%)”“0 (0)”
Urgency“23 (20.5%)”“0 (0)”
Dysuria“21 (18.8%)”“0 (0)”
Hematuria“15 (13.4%)”“0 (0)”
Study limitations
Summary: limitations of the BOND-003 Cohort C evidence
  • Design: Cohort C is a single-arm, open-label trial with no concurrent control. The FDA 2024 draft guidance states that time-to-event endpoints are “uninterpretable in a single-arm trial” and that the lack of a comparator arm makes attributing adverse events difficult; cystectomy-free survival, progression-free survival, and duration of response therefore have no comparator in this trial. The FDA 2018 guidance states that patient and provider preferences “can confound the interpretation” of cystectomy delay, particularly in single-arm trials.
  • Primary endpoint: complete response at any time includes participants with persistent disease who underwent repeat induction treatment, which a later trial of another agent did not permit. At the June 23, 2025 cutoff, 83 of 110 participants (75.5%) had a complete response at any time, while landmark complete response rates were 46.4% (51 of 110) at 12 months and 41.8% (46 of 110) at 24 months.
  • Populations: 115 participants were enrolled, 112 were treated and form the safety population, and 110 who completed the 3-month assessment form the efficacy population. Eligibility required pathologically confirmed BCG-unresponsive CIS, ECOG performance status 0 to 2, and medical ineligibility for, or refusal of, radical cystectomy; prior systemic treatment for bladder cancer other than checkpoint inhibitors was excluded.
  • Sources: the peer-reviewed report is available only as an abstract in the sources read, and most results beyond the abstract (12-month and 24-month landmark rates, duration of response, cystectomy outcomes, subgroups) come from company-sponsored congress presentations, press releases, and filings. The trial was funded by CG Oncology. The prespecified statistical threshold for the primary endpoint was not found in the public sources read; the company states that the trial “met its primary endpoint with statistical significance”.
  • Figures that differ between documents for the same June 23, 2025 cutoff: duration of response at 12 and 24 months of 64.1% and 58.3% (September 2025 press release) against 64.2% and 60.1% (2026 press release and presentation); freedom from progression to muscle-invasive disease of 96.4% (106 of 110) against 96.6%; a lower 95% confidence bound for the 12-month landmark of 36.9% against 36.8%; 24-month cystectomy-free survival of 81.3% against 85% in a translational presentation; and the second serious treatment-related adverse event named as clot retention in a 2026 company presentation and the Form 10-K and as urinary bladder haemorrhage in the publication.
  • Dose: the publication states a dose of “1 × 1012 viral particles per 0·8 mL”, and the company annual report states “1x1012 VPs per milliliter”.
  • Applicability: Cohort C used a five-step instillation process that included saline and DDM washes; the company states that all later studies use a two-step process. No health-related quality-of-life or patient-reported outcome results were found.

BOND-003 cohort P

Objective
Location and study date
Registry dates for the whole BOND-003 study
Study design
Eligibility criteria
Cohort P inclusion criteria

“Have ECOG performance status of 0 to 2.” (opens the source at this quote in a new tab)

“Have pathologically confirmed (WHO grading system employed for tumor grading) (Compérat 2019) BCG-unresponsive HG Ta/T1 papillary disease without CIS.” (opens the source at this quote in a new tab)

“Pathologically confirmed recurrent HG Ta/T1 papillary disease without CIS within 6 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).” (opens the source at this quote in a new tab)

“Patients with HG Ta: Completion of qualifying BCG treatment (e.g., "5+2" minimum exposure) within 12 months of the initial qualifying dose of BCG” (opens the source at this quote in a new tab)

“Patients with HG T1: Patients may be eligible after the initial induction alone (5 of 6 doses of an induction course) as the qualifying BCG treatment.” (opens the source at this quote in a new tab)

“Completion (last dose) of qualifying BCG treatment within 12 months of study enrollment.” (opens the source at this quote in a new tab)

“Pathological confirmation of BCG-unresponsive HG Ta/T1 papillary disease without CIS within 14 days of study enrollment.” (opens the source at this quote in a new tab)

“Have all Ta and/or T1 disease resected, prior to study treatment (e.g., prior to Day 1 treatment).” (opens the source at this quote in a new tab)

“Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using high-grade event-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Efficacy population stated in the November 2026 investor presentation
FieldCretostimogene, BOND-003 Cohort P
Efficacy population“N=54”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and disease characteristics of the safety dataset
Characteristicn%
Male“44”“78.6”
Female“12”“21.4”
Age, mean (SD), years“71.6 (9.3)”
Age, median (range), years“74.0 (45-87)”
Age < 65 years“13”“23.2”
Age ≥ 65 and < 75 years“18”“32.1”
Age ≥ 75 years“25”“44.6”
ECOG PS 0“48”“85.7”
ECOG PS 1“8”“14.3”
HG Ta at study entry“33”“58.9”
HG T1 at study entry“23”“41.1”
Prior BCG instillations, median (range)“9.0 (5 – 21)”
Tumor stage at study entry as stated in November 2026
Characteristicn%
HG Ta at study entry“37”“66.1”
HG T1 at study entry“19”“33.9”
Efficacy results
High-grade event-free survival by tumor stage
Twelve-month and 24-month estimates as of November 2026
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse events reported in more than 10% of participants
Preferred termAny grade, n (%)Grade ≥ 3, n (%)
Participants with ≥1 TRAE“40 (71.4%)”“0 (0)”
Bladder spasm“26 (46.4%)”“0 (0)”
Dysuria“22 (39.3%)”“0 (0)”
Pollakiuria“14 (25.0%)”“0 (0)”
Urgency“11 (19.6%)”“0 (0)”
Study limitations
Summary: limitations of the Cohort P evidence
  • Design: Cohort P is a single-arm, open-label cohort with no concurrent control. FDA guidance recommends a randomized, controlled design with a time-to-event endpoint for disease resected at or before trial entry and states that “Time-to-event endpoints are uninterpretable in a single-arm trial”.
  • Maturity: all reported efficacy results come from one data cutoff (September 1, 2025), at a median follow-up of 6.0 months. Of 56 participants in the safety dataset, 51 were efficacy evaluable, and 5 censored participants were pending efficacy assessment. Twelve-month estimates were “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
  • Publication status: the results have been reported in congress presentations, company filings, and press releases. No peer-reviewed publication of Cohort P was identified.
  • Primary endpoint wording: the registry states a high-grade event-free survival endpoint (“all-cause High Grade Event Free Survival (HG-EFS)”), while one passage of the Form 10-K states that the primary endpoint “is overall event-free survival” and another passage of the same filing states that it “is HG-EFS”. The SUO 2025 slide labels the same three Kaplan-Meier estimates HG-RFS.
  • Sample size: the registry target is 75 participants, while 56 participants were in the safety dataset at the data cutoff, and a 2025 trial-in-progress poster reported “Completed Enrollment”. The registry still lists Cohort P as open to enrollment. The 2026 investor presentation gives an efficacy population of “N=54”, against 51 efficacy-evaluable participants in the congress presentations.
  • Inconsistent figures for the same data cutoff: the SUO 2025 podium reports 33 HG Ta (58.9%) and 23 HG T1 (41.1%) participants and one 2026 poster reports 8 re-induced participants; another 2026 poster reports 37 HG Ta (66.1%) and 19 HG T1 (33.9%) participants and 11 re-induced participants. The Form 10-K lists hematuria among the most common TRAEs, which the SUO 2025 table of TRAEs does not include.
  • Regulatory role: company documents describe the cohort as “Phase 3”, as “an exploratory study”, and as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the BLA would be broadened to include high-grade papillary-only disease.
  • Generalizability: 96.4% of participants were enrolled in the US, 87.5% were White, and 85.7% had ECOG performance status 0. No health-related quality of life or patient-reported outcome results were identified.
  • Comparisons: sponsor materials set Cohort P estimates beside results of other agents from separate trials; the investor presentation states that these data are not based on head-to-head or comparator studies.

CORE-001

Objective
Location and study date
Study dates, enrollment, and sites in the ClinicalTrials.gov record
Study characteristicQuoted record
Study start (actual)“2020-12-08”
Primary completion (actual)“2023-03-07”
Study completion (actual)“2024-05-28”
Enrollment (actual)“35”
Sites“This study has 19 locations”
Enrollment by country in the published final results
Study design
Single-arm, open-label design in the ClinicalTrials.gov record
Design characteristicQuoted record
Phase“Phase 2”
Allocation“N/A”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Collaborator“Merck Sharp & Dohme LLC”
Eligibility criteria
Key inclusion criteria in the clinical study protocol

“Be ≥18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.” (opens the source at this quote in a new tab)

“Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.” (opens the source at this quote in a new tab)

“Relapsed or persistent CIS (with or without TaHG or T1 disease) within 12 months of the completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, TaHG, T1, or a combination of these HGUC pathologies).” (opens the source at this quote in a new tab)

“Pathological confirmation of BCG unresponsive CIS within 10 weeks of study enrollment.” (opens the source at this quote in a new tab)

“CIS specimen must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.” (opens the source at this quote in a new tab)

“Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment (e.g., prior to Day 1 treatment).” (opens the source at this quote in a new tab)

“At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 3 doses of maintenance therapy, OR” (opens the source at this quote in a new tab)

“At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 6 doses of a second induction course.” (opens the source at this quote in a new tab)

“Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using complete response at 12 months as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the published final results
Characteristicn = 35
Age, median“72”
Age, range“57–90”
Sex, male“33 (94.3)”
Sex, female“2 (5.7)”
ECOG 0“25 (71.4)”
ECOG 1“9 (25.7)”
ECOG 2“1 (2.9)”
Race, White“27 (77.1)”
Race, Black/African American“2 (5.7)”
Race, Asian“5 (14.3)”
Race, unknown“1 (2.9)”
Stage, CIS“27 (77.1)”
Stage, CIS + high-grade Ta“4 (11.4)”
Stage, CIS + high-grade T1“4 (11.4)”
Prior BCG courses, 2“18 (51.4)”
Prior BCG courses, 3“8 (22.9)”
Prior BCG courses, 4“2 (5.7)”
Prior BCG courses, 5“4 (11.4)”
Prior BCG courses, ≥6“3 (8.6)”
Prior BCG instillations and persistent or recurrent disease in the interim presentation
CharacteristicQuoted value
Number of prior BCG instillations, median (range)“12 (9 - 30)”
Persistent high-risk NMIBC, n“21”
Persistent high-risk NMIBC, %“60”
Recurrent high-risk NMIBC, n“14”
Recurrent high-risk NMIBC, %“40”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse effects by maximum severity
Preferred termGrade 1, n (%)Grade 2, n (%)Grade 3, n (%)Total (N = 35), n (%)
Participants with at least one study drug-related treatment-emergent adverse effect“9 (25.7)”“18 (51.4)”“5 (14.3)”“32 (91.4)”
Bladder spasm“13 (37.1)”“4 (11.4)”“0”“17 (48.6)”
Fatigue“11 (31.4)”“2 (5.7)”“0”“13 (37.1)”
Dysuria“8 (22.9)”“1 (2.9)”“0”“9 (25.7)”
Pollakiuria“8 (22.9)”“1 (2.9)”“0”“9 (25.7)”
Hematuria“5 (14.3)”“1 (2.9)”“0”“6 (17.1)”
Micturition urgency“4 (11.4)”“2 (5.7)”“0”“6 (17.1)”
Diarrhea“4 (11.4)”“0”“1 (2.9)”“5 (14.3)”
Nocturia“3 (8.6)”“1 (2.9)”“0”“4 (11.4)”
Hypothyroidism“1 (2.9)”“3 (8.6)”“0”“4 (11.4)”
Urinary tract infection“3 (8.6)”“1 (2.9)”“0”“4 (11.4)”
Blood alkaline phosphatase increased“0”“0”“1 (2.9)”“1 (2.9)”
Ejection fraction decreased“0”“0”“1 (2.9)”“1 (2.9)”
Neutrophil count decreased“0”“0”“1 (2.9)”“1 (2.9)”
Adrenal insufficiency“0”“0”“1 (2.9)”“1 (2.9)”
Immune-mediated hepatitis“0”“0”“1 (2.9)”“1 (2.9)”
Study limitations
Summary

CORE-001 was a single-arm, open-label phase 2 trial of 35 participants with no control arm, so the contribution of cretostimogene to the combination cannot be separated from that of pembrolizumab within the trial. The protocol tested a 12-month complete response rate of 19% (H0) against 36% (Ha) at a one-sided alpha of 0.10 with approximately 81% power, and required 30 evaluable participants. The 12-month complete response rate was 57.1% (20 of 35; 95% CI 40.7% to 73.5% in the publication and 39.5% to 73.2% in the annual report). The 24-month complete response rate was 51.4% (18 of 35) in the publication and 54% (19 of 35) at the later May 17, 2024 data cutoff reported by the company. Long-term efficacy and survival follow-up stopped under Protocol Amendment 7, so data beyond 24 months were not collected. Thirty of 35 participants (85.7%) were enrolled in the USA and 5 (14.3%) in Korea; 33 (94.3%) were male. Pembrolizumab dosing changed during the trial from 200 mg every 3 weeks to 400 mg every 6 weeks, and the DDM concentration is described as 5% in the protocol synopsis and registry record and as 0.1% in the protocol administration procedure. An author correction removed the abstract statements that attributed immune-related adverse effects exclusively to pembrolizumab, and added that attribution of adverse effects to pembrolizumab was “assessed by the treating physicians”. Long-term follow-up assessments were based on local review.

BOND-002

Objective
Location and study date
Registered study dates and sites
FieldQuoted record
Study start (actual)“2015-06-02”
Primary completion (actual)“2018-08”
Study completion (actual)“2019-02”
Number of sites“This study has 17 locations”
Principal investigator“Gary Steinberg, MD”
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using durable complete response at 18 months as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (actual)“66”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary: limitations of BOND-002
  • Design: BOND-002 was a phase 2, open-label, single-arm study with no comparator arm.
  • Population: the 10-K describes the enrolled population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. Eligibility allowed participants whose second BCG course had as few as two weekly treatments, and 19 of the 65 enrolled participants had Ta/T1 disease alongside 46 with CIS, so the population differs from the BCG-unresponsive population of BOND-003.
  • Endpoint reporting: the registered primary endpoint is durable complete response lasting 12 months or longer and assessed at 18 months. The only peer-reviewed report is an interim analysis of 45 participants that reported complete response at 6 months (47%). The final figures (40 of 65 participants, 61.5%, with complete response at any time; 30 of 46 participants, 65.2%, with CIS-containing disease) come from company filings, and no peer-reviewed report of the registered primary endpoint was identified.
  • Enrollment counts differ by source: the registry lists 66 participants enrolled, and the 10-K reports 65 enrolled per protocol, with 3 additional treated participants in the safety set.
  • Regimen: maintenance in BOND-002 was six weekly instillations at months 6, 12, and 18, a schedule that differs from the one used in BOND-003.
  • No results posted on ClinicalTrials.gov were identified.

BOND

Objective
Location and study date
Registered study dates and sites
FieldQuoted record
Study start“2014-03”
Primary completion (actual)“2016-06”
Number of sites“This study has 7 locations”
Study chair“Alex W Yeung, MBBS”
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using complete response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (actual)“22”
Description of analysis sets

No evidence found.

Results
Participant disposition
Study termination
FieldQuoted record
Reason for stopping“Change in study design”
Study completion (actual)“2016-06”
Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations of BOND
  • BOND was registered as an integrated phase 2/3, open-label, randomized study of CG0070 against investigator choice of mitomycin C, interferon, valrubicin, or gemcitabine in participants with CIS-containing disease after BCG.
  • The registry lists the study as terminated for a “Change in study design” with 22 participants enrolled, from March 2014 to June 2016.
  • No results posted on ClinicalTrials.gov and no publication or company report of its efficacy or safety results were identified, so the study contributes no efficacy or safety data to this report.
  • Eligibility allowed participants who had been “successfully treated with BCG, but subsequently found to have recurrence”, so the registered population differs from the BCG-unresponsive population of BOND-003.

V-0046

Objective
Location and study date
Registered study dates, sponsor, and sites
FieldQuoted record
Study start“2005-04”
Primary completion (estimated)“2008-10”
Study completion (estimated)“2010-09”
Number of sites“This study has 10 locations”
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (estimated)“75”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Complete response at 3 months by schedule: company presentation
ScheduleComplete response at 3 months
Single dose“3/13 (23%)”
Every 28 days“6/13 (46%)”
Weekly × 6“7/9 (78%)”
Multi-dose (every 28 days and weekly × 6)“13/22 (59%)”
Total“16/35 (46%)”
Complete response at 3 months by dose: company presentation
DoseComplete response at 3 months
1 × 10^12 viral particles“8/13 (62%)”
3 × 10^12 viral particles“4/9 (44%)”
1 × 10^13 viral particles“4/10 (40%)”
3 × 10^13 viral particles“0/3 (0%)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary: limitations of V-0046
  • Design: V-0046 was a phase 1, open-label, non-randomized dose-escalation study in 35 participants, with cohorts of three to six participants at each dose and schedule, so efficacy estimates rest on small subgroups (for example, 9 participants on the weekly × 6 schedule).
  • Population: eligibility required failure of at least one prior BCG treatment and allowed G2 disease, which differs from the BCG-unresponsive definition used in BOND-003.
  • Reported results differ by source: the 2012 publication reports a complete response rate of 48.6% with a median duration of 10.4 months, a 2010 congress report gives 46%, and a 2023 company presentation gives 16 of 35 participants (46%) at 3 months with a median duration of 8.4 months. The multi-dose complete response rate is 63.6% (14 of 22) in the publication and 13 of 22 (59%) in the presentation.
  • The association between retinoblastoma phosphorylation and response (81.8%, 9 of 11) comes from an exploratory, retrospective assessment of a subset of 18 participants.
  • The registry record lists an estimated primary completion in October 2008 and an estimated enrollment of 75 participants, against 35 participants treated.
  • Only the abstract of the 2012 publication is openly available.